Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Puma Biotechnology's pe ratio was 15.5× on Nov 11, 2026, against 6.8× a year earlier. Over the last 4 years it ranged from 4.0× to 58.8×, with a median of 11.8×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 15.5× | +7.5 |
| 2025 | Dec 31, 2025 | 8.0× | +1.7 |
| 2024 | Dec 31, 2024 | 6.4× | −47.8 |
| 2023 | Dec 29, 2023 | 54.1× | +34.9 |
| 2022 | Dec 30, 2022 | 19.2× | – |
See a number that looks wrong?